Welcome to our dedicated page for Bright Minds Biosciences news (Ticker: DRUG), a resource for investors and traders seeking the latest updates and insights on Bright Minds Biosciences stock.
Bright Minds Biosciences Inc. (DRUG) generates news flow centered on its clinical-stage neuroscience pipeline and capital markets activity. As a biotechnology company focused on neurological and psychiatric disorders, its announcements frequently cover clinical trial milestones, data readouts and new program launches for conditions such as drug-resistant epilepsy, developmental and epileptic encephalopathies (DEE), Prader-Willi Syndrome (PWS), depression and other central nervous system disorders.
Recent news has highlighted topline Phase 2 results from the BREAKTHROUGH trial of BMB-101 in adult patients with drug-resistant absence seizures and DEE. The company reported that the study met primary efficacy endpoints in both cohorts, with seizure reductions and a safety and tolerability profile it describes as favorable. Updates have also included details on REM sleep findings in absence seizure patients and plans to prepare global registrational trials in absence seizures and DEE.
Investors following DRUG news will also see coverage of Bright Minds’ expansion into PWS, including initiation of the NOVA Phase 2a study of BMB-101 in PWS patients and nomination of BMB-105 as a new clinical candidate. The company has announced additions to its scientific advisory board featuring recognized PWS experts, along with explanations of the NOVA study design and its focus on hyperphagia-related behaviors and neurobehavioral symptoms.
Another recurring news theme is preclinical data from its serotonergic agonist platform, such as reports that BMB-201 outperformed sumatriptan in a validated vascular headache model. Capital markets updates, including the launch, pricing and closing of a US$175 million public offering of common shares under a Form F-3 shelf registration, also feature prominently. Readers who monitor this page can review these clinical, scientific and financing developments as Bright Minds advances its CNS-focused pipeline.
Bright Minds Biosciences (Nasdaq: DRUG) announced the successful completion of 28-day repeat-dose toxicity studies for its lead product, BMB-101, with no major toxicological findings observed. Conducted by ITR Laboratories Canada, the studies confirmed that BMB-101 was well tolerated in both mice and dogs at doses of up to 40 and 30 mg/kg/day, respectively. The results support the forthcoming first-in-human clinical trial anticipated in Q2 2022. Dr. Revati Shreeniwas noted the potential of BMB-101 as a treatment for Dravet Syndrome, highlighting a significant unmet need in this area.
Bright Minds Biosciences (NASDAQ: DRUG) announced that management will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:00 PM ET. The presentation will focus on the company's work in developing novel treatments for neuropsychiatric disorders, epilepsy, and pain, particularly BMB-101. This selective serotonin agonist shows promise in treating conditions like Dravet syndrome and mental health disorders. An archived version will be available on the company’s website for 90 days post-conference.
Bright Minds Biosciences (BMB) announced a virtual presentation by CEO Ian McDonald and CSO Alan Kozikowski at the H.C. Wainwright Bioconnect Conference on January 10, 2022, starting at 7:00am ET. The presentation will cover their innovative drug development targeting neuropsychiatric disorders and epilepsy. The company is focused on advancing BMB-101, a selective serotonin receptor agonist, showing potential in treating addiction and impulsive behaviors. A replay of the presentation will be available on their website for 90 days after the event.
Bright Minds Biosciences (BMB) announced CEO Ian McDonald will present virtually at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021, at 3:00 PM ET. The conference will feature a webcast, with an archived replay available on the company's website for 90 days. Bright Minds is focused on developing innovative treatments for neuropsychiatric disorders, epilepsy, and pain. Its investigational drug BMB-101 shows promise in treating conditions like Dravet syndrome and mental health disorders by targeting serotonin receptors involving crucial neurotransmitter pathways.
Bright Minds Biosciences (BMBIF, DRUG) announced significant advancements in its 5-HT2A psychedelic drug discovery program. The company has synthesized hundreds of novel compounds and aims to announce its lead molecule by Q1 2022. Utilizing advanced drug design and preclinical modeling, Bright Minds aims to develop safer, more potent treatments for neuropsychiatric disorders, including depression and PTSD. The potential market for mental health drugs is projected to grow from $37 billion in 2020 to $59 billion by 2031, highlighting a significant commercial opportunity for the company.
Bright Minds Biosciences (BMB) announced its common stock will be listed on the Nasdaq Capital Market under the ticker symbol 'DRUG' starting November 8, 2021. This listing is seen as a milestone, aiming to enhance shareholder returns and market presence. The company is advancing its lead drug candidate, BMB-101, targeting Dravet syndrome, with first-in-human trials expected in H1 2022. BMB focuses on innovative treatments for neuropsychiatric disorders, leveraging serotonin agonists to tackle difficult-to-treat conditions.